Differences in Biologic Persistence in PsO and PsA Administrative claims analysis of biologic use in PsO and PsA in French health insurance databases shows that despite widespread biologic use, overall drug persistence was low for PsO and PsA biologics. https://t.co/PtrXu9xyFa https://t.co/RWciF4DqXj